A Phase I Trial to Evaluate the Pharmacokinetics, Safety and Immunogenicity of Subcutaneously Administered Biosimilar SCB-808 and Originator Drug Enbrel in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Etanercept (Primary)
- Indications Autoimmune disorders; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Clover Biopharmaceuticals
- 01 Aug 2018 According to a Clover Biopharmaceuticals media release, the first patient from this trial has been dosed.
- 01 Aug 2018 Status changed from planning to recruiting, according to a Clover Biopharmaceuticals media release.
- 28 Dec 2017 New trial record